FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2783127030> ?p ?o ?g. }

• W2783127030 abstract "AIM AND OBJECTIVES: Almost all drugs have side effects, this is due to toxic nature of the drug entity. Furtherdue to the travelling or mailing of drug to one place to another place in body may produce sideeffects in different organs unnecessarily. So it is necessary to achieve the drug to specifictargeted site. Lot of approaches is available. But most of the approaches are having practicaldifficulties. One of the good and significant approaches is to deliver the drug as floating tablets,which is termed as floating drug delivery systems.The present research focused on the delivery of candesartan cilexetil via floating drugdelivery system. This remains in the site of application i.e. in GIT. By this the degradation ofdrug is minimized. Further it may produce good therapeutic concentration in the system.Floating drug delivery systems can remain in the gastric region for several hours andhence significantly prolong the gastric residence time of drugs. Prolonged gastric retentionimproves bioavailability, reduces drug waste, and improves solubility for drugs that are lesssoluble in a high pH environment.Hypertension is a chronic disease condition in which the systemic arterial bloodpressure is elevated. Anti-hypertensive drugs are used in the treatment of several cardiovasculardisorders, particularly angina pectoris, supraventricular tachycardia and hypertension.Candesartan Cilexetil, an antihypertensive drug competes with angiotensin II forbinding at the AT1 receptor subtype. As angiotensin II is a vasoconstrictor which alsostimulates the synthesis and release of aldosterone, blockage of its effects results in a decreasein systemic vascular resistance.The present work was aimed to prepare floating tablets of Candesartan Cilexetil withincreased bioavailability and controlled release property. SUMMARY: Oral delivery of drugs is one of the most preferable routes of delivery due to the ease ofadministration, patient compliance and flexibility in formulation etc.Floating systems significantly extend the period of time, over which drug maybe released and prolongs dosing intervals and increase patient compliance. Thesesystems retain in stomach and improve the absorption window and thus enhance thebioavailability.Floating dosage forms are oral dosage forms of tablets, capsules, or micro beadsand contain hydrocolloids that allow floating by swelling thereby prolong the residencetime of dosage form within G.I tract.Floating drug delivery or gastroretentive systems gastric emptying is anextremely variable process and ability to prolong and control the emptying time is avaluable asset for dosage forms, which reside in the stomach for a longer period of timethan conventional dosage forms.Floating drug delivery system (FDDS) could prolong GRT to obtain sufficientdrug bioavailability . The system basically floats in the gastric fluid because of itslower density compared to that of the aqueous medium. FDDS is desirable for drugswith an absorption window in the stomach or in the upper small intestine.Certain factors like density, size, shape, fast or fed conditions, nature of meal,age, posture, other drugs, biological factors may affect the gastric retention.Candesartan cilexetil is a drug used in the treatment of hypertension. In thepresent project floating tablets were designed and executed.Floating tablets of candesartan cilexetil were developed to prolong gastricresidence time and to increase its bioavailability.Six formulations (CF1 to CF6) of floating tablets of candesartan cilexetil wereprepared by using individual and combination of polymers. HPMC, carbopol 934 andxanthum gum were used as polymer to retard the release of the drug in controlledmanner.Flow properties of the prepared granules for CF1 – CF6 were determined and itwas found that the results were within the standard limits and specifications.The floating tablets were prepared by direct compression method. Directcompression method is a suitable method for drugs which are sensitive to heat andmoisture. Probably it saves the time also. In the present project the formulations wereeasily and quickly prepared because of the employment of direct compression.The compressed tablets (CF1 – CF6) were evaluated for various tests qualitycontrol tests weight variation, content uniformity, friability, hardness, floating time,floating lag time and in vitro release studies.The hardness and friability of the tablets (CF1 – CF6) were within the limits.The weight variations of the tablets (CF1 – CF6) were found to be within thelimits.The content uniformity of the prepared tablets (CF1 – CF6) were within thelimits.The floating time and floating lag time for the prepared formulations (CF1 –CF6) was good.From the in vitro release studies the trials CF1, CF2, CF3, CF4, CF5 and CF6percent release at the end of the 24th hour was found to be 69.22±0.36, 66.33±0.12,89.63±0.41, 92.33±0.21, 99.12±0.43, and 93.19±0.55 respectively. From the in vitrorelease results it was found that the trial CF5 was best amongst the trials. The formulation (CF5) with hydroxypropylmethyl cellulose and xanthum gumwas found to be best formulation with floating time of 8 hrs and in vitro drug releaseof about 99.12±0.43% at the end of 24th hour.CONCLUSION: The present work was based on the floating drug delivery of candesartan cilexetil.Floating tablets of candesartan cilexetil were formulated and evaluated. Based on the invitro evaluation studies, optimized trial was found to be CF5 with good in vitroproperties.Hence it is ideal to formulate floating tablets for candesartan cilexetil.However in future it is needed to carryout in vivo studies to implement candesartancilexetil as commercial product." @default.
• W2783127030 created "2018-01-26" @default.
• W2783127030 creator A5076319132 @default.
• W2783127030 date "2015-04-01" @default.
• W2783127030 modified "2023-09-27" @default.
• W2783127030 title "Formulation of Floating Tablets of Candesartan Cilexetil with Increased Bioavailibility and Controlled Release Property" @default.
• W2783127030 hasPublicationYear "2015" @default.
• W2783127030 type Work @default.
• W2783127030 sameAs 2783127030 @default.
• W2783127030 citedByCount "0" @default.
• W2783127030 crossrefType "dissertation" @default.
• W2783127030 hasAuthorship W2783127030A5076319132 @default.
• W2783127030 hasConcept C126322002 @default.
• W2783127030 hasConcept C138651985 @default.
• W2783127030 hasConcept C178790620 @default.
• W2783127030 hasConcept C181389837 @default.
• W2783127030 hasConcept C185592680 @default.
• W2783127030 hasConcept C2779820397 @default.
• W2783127030 hasConcept C2780035454 @default.
• W2783127030 hasConcept C2780036600 @default.
• W2783127030 hasConcept C2908929049 @default.
• W2783127030 hasConcept C71924100 @default.
• W2783127030 hasConcept C84393581 @default.
• W2783127030 hasConcept C98274493 @default.
• W2783127030 hasConceptScore W2783127030C126322002 @default.
• W2783127030 hasConceptScore W2783127030C138651985 @default.
• W2783127030 hasConceptScore W2783127030C178790620 @default.
• W2783127030 hasConceptScore W2783127030C181389837 @default.
• W2783127030 hasConceptScore W2783127030C185592680 @default.
• W2783127030 hasConceptScore W2783127030C2779820397 @default.
• W2783127030 hasConceptScore W2783127030C2780035454 @default.
• W2783127030 hasConceptScore W2783127030C2780036600 @default.
• W2783127030 hasConceptScore W2783127030C2908929049 @default.
• W2783127030 hasConceptScore W2783127030C71924100 @default.
• W2783127030 hasConceptScore W2783127030C84393581 @default.
• W2783127030 hasConceptScore W2783127030C98274493 @default.
• W2783127030 hasLocation W27831270301 @default.
• W2783127030 hasOpenAccess W2783127030 @default.
• W2783127030 hasPrimaryLocation W27831270301 @default.
• W2783127030 hasRelatedWork W2112976037 @default.
• W2783127030 hasRelatedWork W2386179211 @default.
• W2783127030 hasRelatedWork W2610657403 @default.
• W2783127030 hasRelatedWork W2782662776 @default.
• W2783127030 hasRelatedWork W2782848336 @default.
• W2783127030 hasRelatedWork W2783278838 @default.
• W2783127030 hasRelatedWork W2783487219 @default.
• W2783127030 hasRelatedWork W2783861488 @default.
• W2783127030 hasRelatedWork W2783869521 @default.
• W2783127030 hasRelatedWork W2797235609 @default.
• W2783127030 hasRelatedWork W2885501355 @default.
• W2783127030 hasRelatedWork W2888049903 @default.
• W2783127030 hasRelatedWork W2889557871 @default.
• W2783127030 hasRelatedWork W2955820824 @default.
• W2783127030 hasRelatedWork W2993256712 @default.
• W2783127030 hasRelatedWork W2183866986 @default.
• W2783127030 hasRelatedWork W2184812848 @default.
• W2783127030 hasRelatedWork W2185653705 @default.
• W2783127030 hasRelatedWork W2561917489 @default.
• W2783127030 hasRelatedWork W3143260113 @default.
• W2783127030 isParatext "false" @default.
• W2783127030 isRetracted "false" @default.
• W2783127030 magId "2783127030" @default.
• W2783127030 workType "dissertation" @default.